For example, there might be a place for Uncaria in the treatment of patients with malignant melanoma since current therapies largely involve specific immunotherapy or chemical inhibitors of signaling molecules (like B-Raf) which are effective only in a subgroup of patients. The gene discussed is BRAF; the disease is melanoma.